← Leaderboards
Jana Portnow
Beckman Research Institute/City Of Hope
$3,811,944
Attributed
$5,621,039
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,671,351 · 7
FDA$595,322 · 1
By mechanism
U19$6,648,482 · 5
R01$2,887,791 · 2
R21$730,400 · 1
Top collaborators
- Karen S Aboody10 shared
- Behnam Badie5 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Behnam Badie$11,237,051
- Jianhua Yu$11,234,533
Others in their field
Top investigators on “Microdialysis”
- Leonard L Howell · Emory University$16,286,809
- Jerome M Siegel · University Of California Los Angeles$14,997,651
- William Joseph McBride · Indiana Univ-Purdue Univ At Indianapolis$12,891,522
- Klaus A Miczek · Tufts University Medford$12,529,122
- David M Holtzman · Washington University$11,460,215
- Sara R Jones · Wake Forest University Health Sciences$10,628,023
Research focus
MicrodialysisSiteNeoplastic CellResearch Project GrantsClinical TrialsDesignGlioblastomaBiological ProductsSmall Molecule InhibitorCorrelative StudyNovel TherapeuticsBrain NeoplasmsInstitutionPrimary Brain NeoplasmsPharmaceutical PreparationsTherapeutic AgentsPilot ProjectsGliomaBrainImmunePre-ClinicalBaseDoseCells
Grant awards (24)
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$925,385
U19 · FY2025 · CA · contact PI
Administrative Core$295,552
U19 · FY2025 · CA · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$882,648
U19 · FY2024 · CA · contact PI
Administrative Core$243,709
U19 · FY2024 · CA · contact PI
Tasquinimod as an adjunct to immunotherapies administered peri-operatively$143,825
U19 · FY2024 · CA · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$917,677
U19 · FY2023 · CA · contact PI
Administrative Core$251,904
U19 · FY2023 · CA · contact PI
Tasquinimod as an adjunct to immunotherapies administered peri-operatively$224,537
U19 · FY2023 · CA · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$920,861
U19 · FY2022 · CA · contact PI
Administrative Core$229,953
U19 · FY2022 · CA · contact PI
Tasquinimod as an adjunct to immunotherapies administered peri-operatively$172,185
U19 · FY2022 · CA · contact PI
Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability$999,063
U19 · FY2021 · CA · contact PI
Administrative Core$233,086
U19 · FY2021 · CA · contact PI
Tasquinimod as an adjunct to immunotherapies administered peri-operatively$208,097
U19 · FY2021 · CA · contact PI
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas$505,496
R01 · FY2019 · CA · contact PI
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas$546,873
R01 · FY2018 · CA · contact PI
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas$1
R01 · FY2017 · CA · contact PI
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas$618,770
R01 · FY2016 · CA · contact PI
Phase 1 Study of Neural Stem Cells & 5-FC/Leucovorin for the Treatment of Recurrent High Grade Gliomas$195,322
R01 · FY2016 · FD · contact PI
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas$621,329
R01 · FY2015 · CA · contact PI
Phase 1 Study of Neural Stem Cells & 5-FC/Leucovorin for the Treatment of Recurrent High Grade Gliomas$200,000
R01 · FY2015 · FD · contact PI
Phase 1 Study of Neural Stem Cells & 5-FC/Leucovorin for the Treatment of Recurrent High Grade Gliomas$200,000
R01 · FY2014 · FD · contact PI
A Pilot Study of 5-FC and Genetically-Modified Neural Stem Cells to Treat Gliomas$365,200
R21 · FY2010 · CA · contact PI
A Pilot Study of 5-FC and Genetically-Modified Neural Stem Cells to Treat Gliomas$365,200
R21 · FY2009 · CA · contact PI